Partner Article
Winsford’s surgical company AMS report pre-tax profit up 16%
Winsford’s surgical and advanced wound-care company, Advanced Medical Solutions Group plc (AMS), reported profit up 16% at £15.2 million.
The company has also agreed a new five year £30 million multi-currency revolving credit facility.
AMS report strong revenue growth across the board with particular success in the USA.
Chief executive officer of AMS, Chris Meredith, said: “2014 has been another year of good growth for AMS, with our three largest business units all delivering solid performances despite challenging currency conditions.
“We were particularly encouraged by strong growth in the US, where the performance, range and pricing of our LiquiBand tissue adhesives is helping to drive gains in market share, and in the UK, where the ActivHeal range continues to provide high performance, cost effective solutions for the NHS.
“The successful launch of the LiquiBand Fix8 hernia mesh fixation device, marking the first use of our medical adhesives in internal applications, demonstrates our continued commitment to investing in innovation.
“With the continuing growth in our larger business units, the strong performance of our products and our ambitions for the Group, we are confident that AMS is well placed to drive growth as well as continued improvements in operational efficiencies and we remain excited by the prospects for our future.”
This was posted in Bdaily's Members' News section by Sophia Taha .
How businesses can reduce workplace safety risks with custom solutions
Tech firm unveils jobs plan after £530,000 backing
SMEs urged to think big at Newcastle event
B Corp is a commitment, not a one-time win
Government must get in gear on vehicle transition
A legacy in stone and spirit
Shaping the future: Your guide to planning reforms
The future direction of expert witness services
Getting people into gear for a workplace return
What to expect in the Spring Statement
Sunderland leading way in UK office supply market
Key construction developments in 2025